Neuberger Berman Group LLC Grows Stock Position in Cytosorbents Co. (NASDAQ:CTSO)

Neuberger Berman Group LLC grew its position in shares of Cytosorbents Co. (NASDAQ:CTSO) by 19.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,801,799 shares of the medical research company’s stock after purchasing an additional 299,103 shares during the period. Neuberger Berman Group LLC’s holdings in Cytosorbents were worth $1,997,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CTSO. Raymond James & Associates purchased a new stake in Cytosorbents during the 4th quarter worth $56,000. Sargent Investment Group LLC boosted its position in Cytosorbents by 4.1% in the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after buying an additional 51,699 shares during the last quarter. Finally, Skylands Capital LLC grew its stake in shares of Cytosorbents by 10.5% during the fourth quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock valued at $3,612,000 after acquiring an additional 309,543 shares in the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Stock Performance

CTSO opened at $0.90 on Monday. The company has a 50-day moving average of $0.89 and a 200-day moving average of $1.06. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.49 and a quick ratio of 1.21. Cytosorbents Co. has a 1-year low of $0.78 and a 1-year high of $4.29.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. The firm had revenue of $9.79 million during the quarter, compared to analyst estimates of $9.78 million. During the same period in the previous year, the company earned ($0.17) earnings per share. As a group, analysts forecast that Cytosorbents Co. will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

CTSO has been the topic of several recent analyst reports. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Tuesday, May 7th. StockNews.com started coverage on Cytosorbents in a research report on Sunday. They issued a “hold” rating on the stock. Finally, B. Riley reissued a “buy” rating and set a $3.00 price target on shares of Cytosorbents in a research report on Wednesday, May 15th.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.